From the Guidelines
A patient taking 2 mg of a medication would need to be converted to Mounjaro, but since Mounjaro is already measured in milligrams and has a standard starting dose of 2.5 mg, the patient should confirm with their healthcare provider whether they meant 2.5 mg, as 2 mg is a non-standard dose. The provided evidence from the study published in Anaesthesia in 2025 1 shows the properties of different GLP-1 receptor agonists, including Mounjaro (tirzepatide). Some key points to consider when converting to Mounjaro include:
- Mounjaro comes in pre-filled pens with doses of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg, as stated in the study 1.
- The standard starting dose for Mounjaro when used for type 2 diabetes is 2.5 mg, which is a once-weekly subcutaneous injection.
- Patients should follow their healthcare provider's instructions regarding proper injection technique, storage requirements, and timing of doses to ensure optimal effectiveness of the medication. It's essential to prioritize the patient's safety and well-being by confirming the intended dose with their healthcare provider to avoid any potential errors or adverse effects.
From the Research
Conversion to Mounjaro
- The provided studies do not directly address the conversion of a 2 mg dose to Mounjaro (tirzepatide) in milligrams.
- Mounjaro is administered via injection, with typical doses ranging from 2.5 to 5 mg once weekly, with a starting dose of 2.5 mg and a maximum dose of 5 mg once weekly 2.
- However, there is no direct conversion provided in the studies for a 2 mg dose to Mounjaro.
- It is essential to consult the prescribing information or a healthcare professional for guidance on dosing and conversion to Mounjaro.
Dosing Information
- The SURPASS-1 trial evaluated the efficacy and safety of tirzepatide monotherapy in patients with type 2 diabetes, with doses of 5,10, and 15 mg once weekly 2.
- The study found that tirzepatide induced a dose-dependent body weight loss, ranging from 7.0 to 9.5 kg, and improved glycemic control without increased risk of hypoglycemia.
- However, the dosing information provided in the studies does not include a direct conversion for a 2 mg dose to Mounjaro.
Safety and Efficacy
- The studies suggest that tirzepatide is effective in improving glycemic control and body weight in patients with type 2 diabetes, with a safety profile consistent with GLP-1 receptor agonists 3, 4, 5, 2.
- However, the provided information does not address the specific question of converting a 2 mg dose to Mounjaro in milligrams.